Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $74.85 Analyst target: $98.89 Upside: 32.12%
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new therapeutic candidates for ophthalmic conditions. The company is headquartered in Irvine, California.
See the full interactive analysis & chart →Informational only — not investment advice.